US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Interim report January – September 2013

    High growth and improved incomeThird quarter: Continuing operations · Sales growth was 33 percent in local currency. Sales amounted to SEK 109 (83) million, corresponding to an increase of 31 percent in SEK. · Operating income (EBIT) amounted to SEK 23 (15) million, corresponding to an operating margin of 21 (18) percent. · The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated. · Net income amounted to SEK 17 (9) million, which gave earnings per share of SEK 0.85 (0.45). · Agreement with Xvivo Perfusion AB to terminate

    Interim report January – June 2013

    Continuing good performanceSecond quarter: Continuing operations · Sales growth was 29 percent in local currency. Sales amounted to SEK 116 (95) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 19 (13) million, corresponding to an operating margin of 16 (13) percent. · The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated. · Net income amounted to SEK 12 (11) million, which gave earnings per share of SEK 0.62 (0.54). · Dividend of SEK 0.60 (0.60) per share, in total SEK 11,

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - June 2013. The presentation will be held in English.Time: Friday, July 12, 2013 at 10 a.m. CET.  Registration can preferably be done in advance under the following link:  https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=187981 or shortly before the conference starts on: · Sweden dial in number: +46 (0)8 5052 0110 · UK dial in number: +44 (0)20 7162 0077

    Interim report January-March 2013: High growth and increased income

    First quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent. · Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38). After the end of the period · During 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with a view to developing a new range of disposable plastic

    Annual report 2012

    Today Vitrolife is publishing the Annual Report for 2012 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.The printed version of the Annual Report will be distributed by mail during the week commencing 15 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual report should be sent to them. The printed version of the Annual Report can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email info@

    Vitrolife has acquired all the shares in HertArt ApS

    In 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with the aim of developing a new range of disposable plastic products for IVF called Labware. Vitrolife acquired 25 percent of the shares in HertArt as part of the collaboration agreement. Vitrolife has now exercised an option to acquire all the shares in the company.In 2010 Vitrolife entered into a collaboration agreement with the then newly formed Danish company HertArt to develop a new range of disposable plastic products for IVF called Labware. Since then HertArt has developed and registered a

    Carsten Browall proposed as new Chairman of Vitrolife AB (publ)

    The Election Committee of Vitrolife AB (publ) has proposed Carsten Browall as the new Chairman of the Board. Carsten Browall is today a member of the company’s Board and he has many years of experience in medical device and the healthcare sector.Vitrolife’s Election Committee today announced that it proposes that the Annual General Meeting elect Carsten Browall as the company’s new Chairman of the Board. Carsten Browall has been a member of the Vitrolife Board since 2012 and has many years of experience from executive positions within medical device and the healthcare sector, amongst other

    Report on operations 2012

    High growth and improved operating marginFourth quarter Continuing operations: · Sales growth was 24 percent in local currency. Sales amounted to SEK 98 (82) million, corresponding to an increase of 20 percent in SEK. · Operating income (EBIT) amounted to SEK 12 (2) million, corresponding to an operating margin of 12 (2) percent. · On October 1 the transplantation business was distributed to the shareholders of Vitrolife, and it is thus reported in this interim report as discontinued operations. The distribution entailed a non-taxable financial capital gain of SEK 303 million

    Conference call on the Report on Operations 2012

    Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2012. The presentation will be held in English.Time: Thursday, February 7, 2012 at 10.00 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=186676 or shortly before time of the conference starts on: Sweden dial in number: +46 (0)8 5052 0110 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 928446 Vitrolife participants:Thomas Axelsson,

    Vitrolife’s share capital and number of shares on November 30, 2012

    As per November 30, 2012, the total number of shares in Vitrolife AB (publ) amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 20,227,554.74.At the beginning of the month the total number of shares in the company amounted to 19,562,769, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,954,024.38 The increase in the number of shares by 268.167 during the month of November is due to the private placement that was directed to the previous owners of Cryo Management Ltd to partly finance the acquisition of Cryo

    Interim report January – September 2012

    Continued strong growth and resolution to distribute TransplantationThird quarterGroup, including discontinuing operations · Sales growth was 17 percent in local currency. Sales amounted to SEK 97 (85) million, corresponding to an increase of 14 percent in SEK. · Sales growth within Fertility was 16 percent in local currency and 13 percent in SEK. Sales growth within Transplantation was 23 percent in local currency and 22 percent in SEK. · Operating income (EBIT) amounted to SEK 13 (14) million. One-time expenses of SEK 5 million were charged against operating income ahead of

    Private placement regarding Cryo Management fully subscribed

    The Extraordinary General Meeting of Vitrolife held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. In accordance with the resolution, the board of directors of Vitrolife has resolved to determine that the company’s share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares. The new share issue was fully subscribed.The Extraordinary General Meeting of Vitrolife held September 24 adopted a resolution regarding a private placement of EUR 1.

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January – September, 2012. The presentation will be held in English.Time: Thursday, November 1, 2012 at 10 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=185569 or shortly before the conference starts on: Sweden dial in number: +46 (0)8 505 201 10 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 924075 Vitrolife participants:

    Election committee for Vitrolife AB (publ)

    The following people have been appointed as members of Vitrolife’s election committee for the Annual General Meeting in 2013:Henrik Blomquist, representing Bure Equity ABJohan Ståhl, representing Lannebo FonderMartin Lewin, representing Eccenovo AB and Thomas OlaussonPatrik Tigerschiöld, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on April 19, 2012. The Annual General Meeting of Vitrolife AB (

    New financial objectives for Vitrolife

    After the adoption of a resolution to spin off Vitrolife’s transplantation business, Vitrolife’s Board has set new financial objectives for the company.Vitrolife’s new financial objectives are as follows: Vitrolife’s Board considers that Vitrolife should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times. Vitrolife’s Board targets a profitable growth. The objective for Vitrolife’s growth over a three year period is an increase in sales by an average

    Interim report January - June 2012

    Strong sales growth in Asia and strengthened operating incomeSecond quarterGroup, including discontinuing operations · Sales growth was 20 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 109 (88) million, corresponding to an increase of 25 percent in SEK. · Sales growth within Fertility was 21 percent in local currency and 25 percent in SEK and was generated primarily by continued strong sales growth in Asia. Sales growth within Transplantation was 18 percent in local currency and 25 percent in SEK. · Operating income (EBIT)

    New management team appointed at Vitrolife

    Vitrolife has appointed a new management team in order to further strengthen the company’s future expansion and competitiveness.Vitrolife announced on July 10 that Maria Forss has been appointed in a new role as Vice President Business Development and Global Marketing. As from October 1, Vitrolife's new management team will consist of Maria Forss, Emma Sjöqvist COO, Christer Silversand CSO, Mikael Engblom CFO and Thomas Axelsson, CEO. No Vice President has been appointed in the Parent Company. "With the latest addition of Maria Forss, Vitrolife has established a very broad and competent

    New Vice President at Vitrolife

    Maria Forss has today been appointed Vice President, responsible for Business Development and Global Marketing. Maria Forss joins Vitrolife from P.U.L.S, where she is responsible for Business Development.Maria has previously worked as the CEO of DuoCort Pharma, and at AstraZeneca in different positions within Marketing and Product Management. Maria takes up her post on October 1. The role of Vice President is new and will strengthen Vitrolife’s management function. “With her solid experience of business development and marketing, Maria will be an excellent asset for us in the work of

    Vitrolife expands its IVF product portfolio through acquisition in the USA.

    Vitrolife is acquiring the business in Conception Technologies, USA. This means that Vitrolife will broaden their IVF product portfolio, increase cost-efficient production capacity and increase its market share, above all in North America.“The broadening of the product portfolio strengthens our product offering. Through our newly expanded sales organization we are able to increase the sales of Conception Technologies products globally. This gives us considerable revenue synergies, which is completely in line with our strategy of exploiting the investments we have made in a global market and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe